News

CRISPR Therapeutics (NASDAQ: CRSP) received great news last week. Its gene-editing therapy, which it has been developing with Vertex Pharmaceuticals, obtained approval from the Food and Drug

Earlier in the pandemic, coronavirus products boosted the revenue and the stock prices of companies selling those products. But these days, those products actually have done just the opposite

You shouldn't have to keep a close eye on your investments. If you find solid stocks to buy, you can leave them in your portfolio and simply wait for their operations to grow and become larger over

When dividend stocks crash in value, that sends their yields up in the opposite direction. But there can be danger for investors who load up on a stock just because its yield is high.

Before buying

Pfizer (NYSE: PFE) was a top performer when the U.S. government was shoveling COVID-related revenue in its direction. Unfortunately, the past year hasn't been nearly as kind. The former high-flying

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are up by more than 11% headed into the latter half of Wednesday's trading session, catapulted higher by the promising results achieved in a mid-stage

Shares of Pfizer (NYSE: PFE) were sinking 8.3% lower as of 11:25 a.m. ET on Wednesday. The sharp sell-off came after the drugmaker provided its guidance for full-year 2024.

Pfizer expects 2024

The human genome project, which was completed in 2003, marked a milestone for biotechnology. It opened the door for the creation of hundreds of medicines based on biology, which have improved the

The stock market looked ready to keep climbing early Wednesday, even as investors were largely in wait-and-see mode during the last day of the Federal Reserve's current monetary policy meeting

Outperforming the benchmark S&P 500 index over a long period is a formidable challenge. This task becomes even more daunting when choosing stocks from the healthcare sector, where the competitive

With AbbVie (NYSE: ABBV) reporting on Nov. 30 that it plans to acquire ImmunoGen, (NASDAQ: IMGN) a biotech developing antibody-drug conjugate (ADC) therapies for various cancers, it's clear that the

The stock market has climbed this year, but that doesn't mean the bargains are over. Many stocks missed out on the rally even though their long-term outlooks remain solid. And these are the stocks

Change the narrative: That's been a classic strategy for businesses facing stiff challenges. And it's a strategy that AbbVie (NYSE: ABBV) appears to have pulled off successfully in recent days.

Vertex Pharmaceuticals (NASDAQ: VRTX) has built a billion-dollar cystic fibrosis (CF) treatment empire, but investors have been looking for something more. They've hoped to see the company broaden

One famous investing maxim advises to buy low and sell high. That's sage advice, but not all stocks are worth investing in while they are down. If they don't go up, you won't have profited from the

I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap.

In today's video I will look at three

While some stocks may not be attracting quite the same hype they were a few years ago, that doesn't mean the quality of their underlying businesses has evaporated. If your intention is to own great

Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. The top drugmaker can't seem to catch a break. Revenue from its COVID-19 products is down big, and

Remember Montgomery Ward, Lehman Brothers, and Pan Am? They were all well-known publicly traded companies that paid dividends. And they all went out of business.

Investors who bought those stocks

Income-seeking investors have some interesting options to choose from in the healthcare sector right now. AbbVie (NYSE: ABBV), the pharmaceutical giant behind the top-selling drug of the past

On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not

As the year draws to a close, it's as good a time as any to review one's investments and consider adding more money into the stock market. The goal shouldn't be to take advantage of the January

As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that

Are you looking for some quality dividend stocks to buy right now? When it comes to investing, it's often a good idea to check out those that haven't been doing too well lately and are trading near

Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the